The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: Current evidence and future perspectives.
Personalized medicine
Preventive treatment
Refractory epilepsy
Seizure
TSC
mTOR inhibitors
Journal
Epilepsy & behavior : E&B
ISSN: 1525-5069
Titre abrégé: Epilepsy Behav
Pays: United States
ID NLM: 100892858
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
25
03
2018
revised:
17
05
2018
accepted:
23
05
2018
pubmed:
27
6
2018
medline:
17
6
2020
entrez:
27
6
2018
Statut:
ppublish
Résumé
Tuberous sclerosis complex (TSC) is one of the most common genetic causes of epilepsy. Mutations in the TSC1 or TSC2 genes lead to the dysregulation of the mechanistic target of rapamycin (mTOR) pathway. This mTOR pathway hyperactivation is associated with several processes resulting in epileptic conditions. The occurrence of seizures and their treatment outcomes seem to play a crucial role in cognitive and behavioral developments in patients with TSC. Mechanistic target of rapamycin inhibitors have been proven to be effective in epilepsy treatment in individuals with TSC. Specifically, because of their disease-modifying mechanism of action, they have the capability to prevent epileptogenesis in patients with TSC. This article will provide an overview of the current evidence of and delineate future perspectives for mTOR inhibitors and their role in preventing epileptogenesis.
Identifiants
pubmed: 29941212
pii: S1525-5050(18)30272-5
doi: 10.1016/j.yebeh.2018.05.039
pii:
doi:
Substances chimiques
Anticonvulsants
0
MTOR protein, human
EC 2.7.1.1
TOR Serine-Threonine Kinases
EC 2.7.11.1
Sirolimus
W36ZG6FT64
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
94-98Informations de copyright
Copyright © 2018 Elsevier Inc. All rights reserved.